20/12/2023
Sunstone Life Science Ventures divests its holding in Arcoma AB Sunstone announces that one hundred percent of the holding in Arcoma AB have been sold in a structured block sale. Sunstone has been a major owner in Arcoma since 2010 and is proud of what the company has...
07/11/2023
Sunstone Life Science Ventures joins EUR 57 Million Series A Investment in Kynexis to Advance Development of Novel Therapeutics for Cognitive Disorders Sunstone Life Science Ventures (Sunstone), a leading Nordic venture capital firm, is excited to announce its...
01/11/2023
Sunstone Life Science Ventures Fund IV invests in DiogenX, a biotech company developing a first-in-class regenerative treatment for type 1 diabetes Sunstone Life Science Ventures (Sunstone), a leading European venture capital firm focused on life science therapeutics,...
16/12/2022
MinervaX announces 72M EUR financing to advance development of novel vaccine against Group B Streptococcus MinervaX ApS, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), today announces the successful...
We use cookies on the website sunstone.eu in order to generate statistics and to maximize user-friendliness and improve functionality. By using our website, you consent to our use of cookies. Click on cookie settings below if you wish to disable cookies. Or you can read more about what cookies are, how we use them and how you disable cookies Here.
Cookie settingsAccept Privacy & Cookies Policy
Recent Comments